Paul Pedersen, MD
General Practice · Barbourville, KYNPI 1003892720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,448 and has fallen 65.0% since, to $507 in 2025. Among general practice clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$807
- Pfizer$677
- Novo Nordisk$529
- AbbVie$501
- Biohaven Pharmaceuticals, Inc.$422
- Ironwood Pharmaceuticals, Inc$402
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,180100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $807 |
| Pfizer | 42 | $677 |
| Novo Nordisk | 46 | $529 |
| AbbVie(2 entities) | 35 | $501 |
| Biohaven Pharmaceuticals, Inc. | 16 | $422 |
| Ironwood Pharmaceuticals, Inc | 30 | $402 |
| Lilly USA, LLC | 30 | $386 |
| Novartis | 18 | $333 |
| Amarin Pharma, Inc. | 25 | $333 |
| Amgen | 13 | $220 |
| Boehringer Ingelheim | 20 | $192 |
| Bayer | 10 | $186 |
| GSK | 10 | $169 |
| Johnson & Johnson | 7 | $118 |
| Astellas Pharma US Inc | 8 | $118 |
| Sanofi-aventis U.S. LLC | 7 | $110 |
| Merck | 6 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Abbott | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 3 | $42 |
| Dexcom, Inc. | 2 | $40 |
| Insulet Corporation | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Upsher-smith Laboratories LLC | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$204
- FARXIGA$125
- BREZTRI$125
How this compares
$6,205 in reported general payments places this provider in the 95th percentile of 1,155 general practice providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 308 | $367,070 |
| EliquisApixaban | 358 | $322,248 |
| JardianceEmpagliflozin | 228 | $228,472 |
| TrulicityDulaglutide | 151 | $200,841 |
| FarxigaDapagliflozin Propanediol | 157 | $127,059 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 96 | $125,290 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 120 | $103,543 |
| Tresiba Flextouch U-200Insulin Degludec | 122 | $98,918 |
| MounjaroTirzepatide | 79 | $91,115 |
| XolairOmalizumab | 20 | $66,692 |
| AustedoDeutetrabenazine | 12 | $64,838 |
| VascepaIcosapent Ethyl | 120 | $57,254 |
| Xigduo XrDapaglifloz Propaned/Metformin | 66 | $56,556 |
| EntrestoSacubitril/Valsartan | 56 | $55,923 |
| LinzessLinaclotide | 64 | $52,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $529 | $492,360404 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Trijardy Xr, Tradjenta | $192 | $424,656471 claims |
| PfizerEliquis, Nurtec Odt | $677 | $345,375380 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $386 | $291,957230 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Bevespi Aerosphere | $807 | $193,164263 claims |
| Johnson & JohnsonInvokana, Xarelto | $118 | $69,69895 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $19 | $64,83812 claims |
| NovartisEntresto | $333 | $55,92356 claims |
| AbbVieLinzess | $501 | $52,25364 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $169 | $39,96846 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $85 | $33,86821 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $23,95938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,155 general practice providers in Kentucky.
Other general practice in Barbourville
- Eric SchneebergerWarsaw$539K
- Stephen SterlitzLexington$263K
- Ryan LewisFrankfort$190K
- Jerome WellbrockCovington$173K
- Shana HughesRussell Springs$85K
- Bryan HarrisLouisville$53K
- Bach NguyenUnion$31K
- Ryan GolibersuchLexington$23K
- Mary ShieldsLouisville$21K
- Beatrice NewellStanton$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.